{
  "consolidation_metadata": {
    "timestamp": "2025-09-19T14:37:53.615977",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "picos",
    "data_split": "test",
    "total_consolidated_picos": 22,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_picos": [
    {
      "Population": "Adults with locally advanced and unresectable or metastatic NSCLC with KRAS G12C mutation who have progressed during or after at least one prior systemic therapy for advanced or unresectable disease, with prior therapy including combined or sequential platinum-containing chemotherapy and anti-PD-1/PD-L1 immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with locally advanced and unresectable or metastatic NSCLC with molecularly diagnosed KRAS G12C mutation. Patients had to have disease progression during or after at least 1 prior systemic therapy for advanced or unresectable stage of the disease. Prior therapy should include combined or sequential platinum-containing combination chemotherapy and an anti-PD-1/PD-L1."
      ],
      "Original_Comparator_Variants": [
        "docetaxel"
      ]
    },
    {
      "Population": "Adults with advanced NSCLC with KRAS G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy and for whom a therapy other than docetaxel is the appropriate patient-individual therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "afatinib, pemetrexed, erlotinib, docetaxel + ramucirumab, docetaxel + nintedanib, vinorelbine (patient-individual therapy, taking into account previous therapy and histology)",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy and for whom a therapy other than docetaxel is the appropriate patient-individual therapy"
      ],
      "Original_Comparator_Variants": [
        "Patient-individual therapy, taking into account previous therapy and histology with selection of afatinib, pemetrexed, erlotinib, docetaxel in combination with ramucirumab, docetaxel in combination with nintedanib and vinorelbine"
      ]
    },
    {
      "Population": "Adults with advanced NSCLC with KRAS G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "atezolizumab"
      ]
    },
    {
      "Population": "Adults with advanced NSCLC with KRAS G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel (only for patients with PD-L1 negative tumours)",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "docetaxel (only for patients with PD-L1 negative tumours)"
      ]
    },
    {
      "Population": "Adults with advanced NSCLC with KRAS G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel in combination with nintedanib (only for patients with PD-L1 negative tumours and adenocarcinoma histology)",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "docetaxel in combination with nintedanib (only for patients with PD-L1 negative tumours and adenocarcinoma histology)"
      ]
    },
    {
      "Population": "Adults with advanced NSCLC with KRAS G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "different chemotherapies without platinum (cisplatin/carboplatin) as well as treatment with an immune checkpoint inhibitor as monotherapy",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "different chemotherapies without platinum (cisplatin/ carboplatin) as well as treatment with an immune checkpoint inhibitor as monotherapy"
      ]
    },
    {
      "Population": "Adults with advanced NSCLC with KRAS G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nivolumab",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "nivolumab"
      ]
    },
    {
      "Population": "Adults with advanced NSCLC with KRAS G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab (only for patients with PD-L1 expressing tumours (PD-L1 expression ≥ 1% of tumour cells))",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "pembrolizumab (only for patients with PD-L1 expressing tumours (PD-L1 expression ≥ 1% of tumour cells))"
      ]
    },
    {
      "Population": "Adults with advanced NSCLC with KRAS G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pemetrexed (only for patients with PD-L1 negative tumours and except in case of predominantly squamous histology)",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "pemetrexed (only for patients with PD-L1 negative tumours and except in case of predominantly squamous histology)"
      ]
    },
    {
      "Population": "Adult patients with advanced NSCLC with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "DK",
        "PT",
        "EN",
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer",
        "adult patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, in case of progression after at least one previous line of systemic therapy"
      ],
      "Original_Comparator_Variants": [
        "docetaxel",
        "docetaxel monotherapy"
      ]
    },
    {
      "Population": "Adult patients with advanced NSCLC with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel + nintedanib",
      "Countries": [
        "PT",
        "EN"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer"
      ],
      "Original_Comparator_Variants": [
        "docetaxel + nintedanib",
        "docetaxel plus nintedanib"
      ]
    },
    {
      "Population": "Adult patients with advanced NSCLC with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pemetrexed",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy"
      ],
      "Original_Comparator_Variants": [
        "pemetrexed"
      ]
    },
    {
      "Population": "Adult patients with advanced NSCLC with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nivolumab",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy"
      ],
      "Original_Comparator_Variants": [
        "nivolumab"
      ]
    },
    {
      "Population": "Adult patients with advanced NSCLC with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy"
      ],
      "Original_Comparator_Variants": [
        "pembrolizumab"
      ]
    },
    {
      "Population": "Adult patients with advanced NSCLC with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy"
      ],
      "Original_Comparator_Variants": [
        "atezolizumab"
      ]
    },
    {
      "Population": "Adult patients with advanced NSCLC with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "platinum doublet",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy"
      ],
      "Original_Comparator_Variants": [
        "platinum doublet"
      ]
    },
    {
      "Population": "Patients with advanced NSCLC with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy and who have been treated with docetaxel or who are not medically suitable for treatment with docetaxel",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best supportive care",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation who have progressed after at least one prior line of systemic therapy and who have been treated with docetaxel or who are not medically suitable for treatment with Docetaxel"
      ],
      "Original_Comparator_Variants": [
        "best supportive care"
      ]
    },
    {
      "Population": "KRAS G12C mutation-positive locally advanced or metastatic NSCLC in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy"
      ],
      "Original_Comparator_Variants": [
        "docetaxel"
      ]
    },
    {
      "Population": "KRAS G12C mutation-positive locally advanced or metastatic NSCLC in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel + nintedanib",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy"
      ],
      "Original_Comparator_Variants": [
        "docetaxel plus nintedanib"
      ]
    },
    {
      "Population": "Patients with Stage IV NSCLC with a KRAS-G12C mutation who have failed at least one systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sotorasib",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "Patients with Stage IV NSCLC with a KRAS-G12C mutation should be treated according to Failure of at least one systemic therapy Targeted therapy"
      ],
      "Original_Comparator_Variants": [
        "Sotorasib"
      ]
    },
    {
      "Population": "Patients with KRAS G12C mutation and performance status 0-2 previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sotorasib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with KRAS G12C and performance status 0-2 and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)"
      ],
      "Original_Comparator_Variants": [
        "sotorasib"
      ]
    },
    {
      "Population": "Patients with KRAS G12C mutation and performance status 0-2 previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "adagrasib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with KRAS G12C and performance status 0-2 and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)"
      ],
      "Original_Comparator_Variants": [
        "adagrasib"
      ]
    },
    {
      "Population": "Patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy"
      ],
      "Original_Comparator_Variants": [
        "docetaxel"
      ]
    }
  ]
}